期刊
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
卷 18, 期 3, 页码 166-170出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MED.0b013e328346938c
关键词
21-hydroxylase deficiency; congenital adrenal hyperplasia; neonatal screening; nonclassic congenital adrenal hyperplasia
资金
- NIDDK NIH HHS [T32 DK065522] Funding Source: Medline
Purpose of review Congenital adrenal hyperplasia (CAH) in children, the majority of which is due to 21-hydroxylase deficiency, represents a group of disorders in which there is impaired cortisol synthesis and abnormalities in adrenal hormonal profiles. There continues to be debate regarding the optimal management of and treatment for these children. This review will highlight the most recent advances in neonatal screening for CAH, as well as the timeliest recommendations for the treatment and management of 21-hydroxylase deficiency, both the classic and nonclassic forms of the disorder. Recent findings Substantive advancements have been made with regard to neonatal screening for CAH, allowing for earlier diagnosis, while minimizing the morbidity and mortality associated with delayed detection. Although the achievement of normal growth and development remains the ultimate goal of treatment, recent studies have provided further insight into the management and refinement of therapy in these children. Summary The optimal management and treatment for children with CAH is still unclear. Although there have been recent advances in the diagnosis and treatment of this group of disorders, there is still much to learn in order to optimize therapy for these individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据